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The impact of TEL-AML1 (ETV6-RUNX1) expression
in precursor B cells and implications for leukaemia using
three different genome-wide screening methods
Y Linka1, S Ginzel2, M Kru¨ger3, A Novosel1, M Gombert1, E Kremmer4, J Harbott5, R Thiele2, A Borkhardt1,6 and P Landgraf1,6
The reciprocal translocation t(12;21)(p13;q22), the most common structural genomic alteration in B-cell precursor acute
lymphoblastic leukaemia in children, results in a chimeric transcription factor TEL-AML1 (ETV6-RUNX1). We identiﬁed directly
and indirectly regulated target genes utilizing an inducible TEL-AML1 system derived from the murine pro B-cell line BA/F3
and a monoclonal antibody directed against TEL-AML1. By integration of promoter binding identiﬁed with chromatin
immunoprecipitation (ChIP)-on-chip, gene expression and protein output through microarray technology and stable labelling of
amino acids in cell culture, we identiﬁed 217 directly and 118 indirectly regulated targets of the TEL-AML1 fusion protein. Directly,
but not indirectly, regulated promoters were enriched in AML1-binding sites. The majority of promoter regions were speciﬁc for the
fusion protein and not bound by native AML1 or TEL. Comparison with gene expression proﬁles from TEL-AML1-positive patients
identiﬁed 56 concordantly misregulated genes with negative effects on proliferation and cellular transport mechanisms and
positive effects on cellular migration, and stress responses including immunological responses. In summary, this work for the
ﬁrst time gives a comprehensive insight into how TEL-AML1 expression may directly and indirectly contribute to alter cells to
become prone for leukemic transformation.
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INTRODUCTION
The reciprocal translocation t(12;21)(p13;q22) is the most frequent
chromosomal rearrangement in childhood B-cell precursor acute
lymphoblastic leukaemia (ALL) with an incidence of B25%.1,2
The resulting TEL-AML1 (syn.: ETV6-RUNX1) expression leads
to expansion of B-cell precursors with enhanced self-renewal
capacity and impaired differentiation to more mature B-cell
stages.3–8 The translocation already occurs in utero in an early
B-cell progenitor cell and leads to establishment of a pre-leukemic
clone persisting in the bone marrow for several years, insufﬁcient
to generate an overt leukaemia.3,9,10 It is unclear if the
translocation inevitably leads to the disease or if only a small
portion progress, as conﬂicting reports about the incidence of this
translocation in healthy newborns exist.3,11
The global binding pattern of the TEL-AML1 fusion protein on
promoter regions in precursor B-cells is not known and
several mechanisms of action have been proposed so far. The
runt-homology DNA-binding domain of AML1 retained in the
TEL-AML1 fusion protein has been shown to be essential for
DNA binding.12 Transiently transfected TEL-AML1 blocks AML1-
dependent transcription of several promoters with requirement of
both, the TEL and AML1 part of the fusion protein.13–15 These
studies proposed that the TEL moiety of the chimeric protein
converts AML1 from an activator to a transcriptional repressor.
However, alternative mechanisms of TEL-AML1 activity have also
been suggested like sequestration of transcriptional cofactors
to the cytoplasm16 or dimerization with wild-type protein.17,18
Studies comparing either patients with and without the
TEL-AML1 fusion19 or TEL-AML1-positive cell lines with small
hairpin RNA-mediated knock down of the fusion protein indicated
expression differences for genes involved in differentiation,
apoptosis and immune responses.20,21 The two latter studies did
not ﬁnd any enrichment for the canonical AML1-binding motif in
regulated genes in the acquired mRNA data.
In this study, we sought to globally identify promoter regions
targeted and regulated by the TEL-AML1 fusion protein.
We wanted to differentiate between direct and indirect regulatory
effects of the TEL-AML1 fusion protein in a cell system void of
secondary aberrations as seen in patients and patient-derived cell
lines by using chromatin immunoprecipitation (ChIP)-on-chip to
identify promoter-binding sites in combination with mRNA
microarray analysis to assess the gene regulatory effect of
TEL-AML1. Furthermore, we analyzed the effect of TEL-AML1
expression on the protein output using stable isotope labelling by
amino acids in cell culture (SILAC) to deduce indirect regulatory
effects of TEL-AML1 independent of promoter binding.
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MATERIALS AND METHODS
Patient samples, control samples and cell lines
Four bone marrow samples of patients with TEL-AML1-positive precursor
B-cell leukaemia at the time of diagnosis and CD19þ MACS (Miltenyi
Biotech, Bergisch Gladbach, Germany)-sorted cells of two healthy donors
were obtained after informed consent. No cytogenetic aberration other
than t(12;21) was detected in those patient samples. The BA/F3-derived
inducible murine cell system was kindly provided by Anthony Ford and has
been described elsewhere.22 BA/F3TAþ bearing the inducible TEL-AML1
plasmid as well as the empty vector control cells (BA/F3TA ) were induced
by 32.5 pM mifepristone treatment for 16 h. NALM-6 (DSMZ ACC 128) and
REH (DSMZ ACC 22) cells were cultured according to the provider. TEL-
AML1 cDNA was generated with overlap extension PCR from TEL (primers:
50-GGCGCTCGCGAATGTCTGAGACTCCTGCTCAG-30 , 50-GGATTCATTCCAAG
TATGCATTCTGCTATTCTCCCAATGGGCATGG-30) and AML1 (primers: 50-CCA
TGCCCATTGGGAGAATAGCAGAATGCATAC TTGGAATGAATCC-30 , 50-CCGCG
ACTAGTTCAGTAGGGCCTCCACACGGCCTC-30),23 cloned into the expression
vector pMC324 and transfected into NALM-6 cells using DMRIE-C
(Invitrogen, Darmstadt, Germany). Stable cell clones were selected using
400mg/ml hygromycin.
Generation and testing of monoclonal antibody against TEL-AML1
(ETV6-RUNX1) fusion protein
A peptide comprising amino acids PIGRIAECILGM (Figure 1a) of TEL- AML1
fusion protein was synthesized and coupled to keyhole limpet hemocyanin
and ovalbumin. Lou/C rats were immunized subcutaneously and
intraperitoneally with a mixture of 50mg peptide-keyhole limpet hemo-
cyanin, 5 nmol CpG oligonucleotide (Tib Molbiol, Berlin, Germany), 500ml
phosphate-buffered saline and 500ml incomplete Freund’s adjuvant.
A boost without adjuvant was given 6 weeks after the primary injection
and fusion of the rat spleen cells with the murine cell line P3 63-Ag8.653
(ATCC CRL-1580) was performed after 3 days. Monoclonal antibodies that
reacted speciﬁcally in ELISA with the immunized peptide were further
analyzed in western blot analysis. Clone ‘TEL 6F2’ of rat IgG2a subclass was
puriﬁed with protein G afﬁnity chromatography with Vivapure maxiprep
spin columns (Sartorius, Goettingen, Germany) and concentrated by
ultracentrifugation (MWco¼ 10 kDa).
Western blotting and ﬂuorescence-activated cell sorting analysis
Procedures were performed as directed by the manufacturer. For western
blotting, antibodies directed against glyceraldehyde 3-phosphate dehydro-
genase (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.
Membranes were incubated with horseradish peroxidase-conjugated sec-
ondary antibodies against rat (R&D Systems, Minneapolis, MN, USA) and
mouse (Santa Cruz Biotechnology) and detection was performed
with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher
Scientiﬁc, Waltham, MA, USA). For ﬂuorescence-activated cell sorting analysis,
500 000 cells were ﬁxed and permeabilized using Cytoﬁx/Cytoperm (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA). Cells were stained either
with TEL-AML1 antibody and secondary anti-rat FITC-conjugated antibody
(Santa Cruz Biotechnology) or with V5-tag antibody already FITC-conjugated
(Abcam, Cambridge, UK).
ChIP and DNA ampliﬁcation
ChIPs were performed as described elsewhere.25 Five microgram of
TEL-AML1 antibody or rat isotype control IgG (Abcam) were incubated with
protein G magnetic beads (Dynal, Invitrogen) pre-blocked with
pre-immunization serum for 6 h at 4 1C. Beads were washed and
incubated with DNA of 1 107 cells sheared to B500 bp length at 4 1C
over night. The mouse endogenous TEL and AML1 proteins were
immunoprecipitated with antibodies anti-TEL (N-19; Santa Cruz
Biotechnology) and anti-AML1 (Ab-1; Calbiochem/Merck, Darmstadt,
Germany). Enrichment of the previously described target promoter
region of Gzmb26 in the samples was analyzed by quantitative real-time
PCR using Sybr Green (Applied Biosystems, Foster City, CA, USA) and
primers following standard procedure. Primer sequences were: Gzmb#1
forward 50-GGACTCTGATACCATAGGCTA-30 , reverse 50-GACTCAGAGAACCA
CCACTTA-30 ; Gzmb#2 forward 50-GTAAGTGGTGGTTCTCTGAGT-30 , reverse
50-CCTGATGACGTCTTCTGAGTA-30 . Chromatin-immunoprecipitated DNA
was ampliﬁed using the GenomePlex Complete Whole Genome
Ampliﬁcation Kit (Sigma-Aldrich Chemie GmbH, Munich, Germany).
Labelling and microarray hybridization on 385K RefSeq mouse promoter
arrays were performed by Source BioScience imaGenes (Berlin, Germany).
Genes corresponding to a peak area with a false discovery rate p0.05 as
calculated from the log2 ratios between the TEL-AML1 ChIP experiment
and input material were identiﬁed with NimbleScan software (Nimblegen
Systems Inc., Madison, WI, USA). Promoter regions with at least 1.5-fold
enrichment over the respective empty vector control were retained
for further analysis. Data were submitted to Gene Expression Omnibus
(GEO Accession number: GSE50736).
Gene expression analysis
Total RNA, isolated from 5 106 cells with standard TRIZOL procedure
(Invitrogen), was labelled using a GeneChip 30 in vitro transcription Express
Kit (Affymetrix, Santa Clara, CA, USA) and hybridized to a GeneChip Mouse
Genome 430 2.0 Array (Affymetrix) following standard procedure.
Bioinformatic data analysis was performed using R 2.15 software,27
Bioconductor 2.1628 and biomaRt 2.12.29 Background correction and
normalization of the probe signals were performed using the GCRMA
package (v.2.28.0).30 mRNAs with a fold change of at least 1.5 between TEL-
AML1 expressing and induced control cells and a P-value p0.05 were
considered signiﬁcant and were retained for further analysis. Data were
submitted to Gene Expression Omnibus (GEO accession number
GSE50736). For human samples, 10 ng of RNA was labelled using Agilent
Low Input Quick Amp Labelling Kit following the manufacturer’s protocol
(Agilent Technologies, Boeblingen, Germany). Hybridization was
performed on the Agilent Whole Human Genome Oligo Microarrays
8 60K using Agilent Gene Expression Hybridization Kit (Agilent
Technologies).
SILAC and mass spectrometric analysis
Cells were grown in cell culture medium deﬁcient for L-arginine and
L-lysine (SILAC RPMI, Thermo Fisher Scientiﬁc), supplemented with 2mM
L-glutamine (Gibco, Invitrogen), 10% dialyzed fetal bovine serum (Invitro-
gen) and amino acids of different molecular weight (0.389mM L-arginine
and 0.789mM L-lysine; Sigma Aldrich) for at least ﬁve doublings. The
‘middle’ medium was supplemented with L-arginine-13C6 and L-lysine-D4,
whereas the ‘heavy’ medium contained L-arginine-13C6
15N4 and
L-lysine-13C6
15N2. Induction of TEL-AML1 expression was performed as
described above. Cells were harvested 16 h after induction and pellets
corresponding to 7 106 cells were ﬂash frozen in liquid nitrogen. Mass
spectrometric analysis of trypsin-digested size-fractionated proteins was
performed as described elsewhere.31,32 Peptides and proteins were
identiﬁed with Mascot (Matrix Science, London, UK) and quantiﬁed with
MSQuant (http://msquant.sourceforge.net) as described previously.32
Data and functional annotation analysis and correlation with gene
ontology (GO)
For deﬁned gene groups, we assigned GO terms, KEGG and Biocarta
pathways, functional categories (COG_ontology, SP-PIR_keywords,
UP_Seq_features), protein domains from interpro, PIR-superfamily and
SMART databases using the DAVID bioinformatics resources 6.7, NIAID/
NIH.33 Enrichment over the whole set of probed genes and heuristic
multiple linkage clustering analysis was performed using the same tools
and Benjamini-Hochberg correction was applied to correct for multiple
testing on the data set.
RESULTS
Identiﬁcation of TEL-AML1 target genes
In an attempt to generate a monoclonal antibody detecting the
TEL-AML1 fusion protein, we used a peptide immunization
approach as outlined in Figure 1a. We conﬁrmed a rapid, strong
and stable TEL-AML1 expression after induction of the previously
described murine BA/F3-related pro-B-cell line.22 In western
blotting analysis, the antibody showed a strong detection of the
fusion protein in BA/F3 cells (Figure 1b), similar to a V5-tag-speciﬁc
antibody. On average, 93.5% of cells (±0.74;±1 s.e.m.) exhibited
expression of TEL-AML1 16 h after induction in ﬂuorescence-
activated cell sorting analysis, whereas non-induced cells did not
show expression of the fusion protein (Figure 1c). However, in REH
cells expressing the fusion protein at lower levels, we could also
detect a band running at the height of either AML or TEL in
western blotting (Supplementary Figure 1). We conclude that the
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antibody not only detects endogenous fusion protein at low
levels, but also cross-reacts with AML1 in REH cells, but not in the
inducible BA/F3 cell line system. Chromatin immunoprecipitation
experiments of TEL-AML1-expressing BA/F3 cells were integrated
with gene expression arrays and differential protein expression
data (SILAC) to investigate and distinguish early direct target
genes from indirect target genes of the chimeric transcription
factor (outlined in Figure 2). The induction of TEL-AML1 results in
binding to promoter regions of 2585 genes identiﬁed in ChIP
experiments and also probed on the mRNA microarray platform,
including granzyme B, a previously classiﬁed TEL-AML1 target.26
Of those 217 exhibited differentially expressed mRNA levels and
were thus identiﬁed as direct targets of TEL-AML1 in our cell line
model (Figure 3, Supplementary Table 1). As DNA binding of the
fusion protein has been thought to be conferred through the
domain of the AML1 part, we performed AML1 immunoprecipita-
tion experiments in the same cell system. Unexpectedly, only 5 of
the directly regulated promoters were also identiﬁed by AML1
ChIP, whereas 10 were identiﬁed by TEL ChIP in this study. Twelve
promoter regions identiﬁed in AML1 ChIP-seq from another
mouse pro-B-cell line BMiFLT3(15–3)34 overlapped with the here
identiﬁed TEL-AML1 directly regulated promoters. Therefore, the
majority (88%) of the identiﬁed gene promoter regions were
speciﬁc for the TEL-AML1 fusion protein. The effect of TEL-AML1
promoter binding on protein output was assessed by SILAC.
Surprisingly, only approximately one-third of the direct TEL-AML1
targets (31genes) showed a signiﬁcant differential expression on
protein level (Table 1). Even when considering only minor protein
changes between induced and not induced cells, the overlap only
increases by eight additional proteins. Indirect effects of TEL-AML1
overexpression were identiﬁed as 118 regulated proteins were
also differentially regulated on the mRNA level but not
immunoprecipitated by TEL-AML1 ChIP (Figure 3, Supplementary
Table 2). The majority of regulated mRNAs and proteins (86.6%)
were regulated in the same direction on protein and mRNA level.
Rab8b was the only gene, whose mRNA was upregulated with
concomitant downregulation of the protein upon TEL-AML1
stimulation. Interestingly, the 30- untranslated region of this mRNA
harbours a predicted binding site for microRNA miR-19a/b, both
upregulated upon TEL-AML1 induction in our cell line model.
We compared the TEL-AML1 occupancy between our mouse cell
line model and the human precursor B-cell line NALM-6 stably
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Figure 1. TEL-AML1 antibody design and specificity testing. (a) Design strategy for the TEL-AML1 antibody. The immunization peptide
spanning the fusion site between the TEL (white) and AML1 (black) fusion partners is indicated. (b) Specificity of the TEL-AML1 antibody.
Western blots (WB) of the parental BA/F3 cell line (TA ) and stable cell lines carrying the inducible TEL-AML1 fusion construct (TAþ ) are
treated with mifepristone as indicated. TEL-AML1 was specifically detected only in the induced cell lines, whereas the AML and TEL antibodies
(right panels) detected both, the fusion protein and the native protein. Please note that the TEL antibody also detects numerous unspecific
bands in the whole-cell lysates. (c) Detection of TEL-AML1 fusion protein by fluorescence-activated cell sorting (FACS) analysis. Induction with
mifepriston resulted in on average 93.5±0.7% (n¼ 15;±1 s.d.) cells carrying the TEL-AML1 fusion protein in FACS analysis using the TEL-AML1
antibody. A representative example is shown. Tightness of the induction system is shown in comparison to parental BA/F3 cells treated with
mifepriston. Abbreviations: FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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transfected with TEL-AML1. Although the human cell line under-
went 3 weeks of selection, many regions precipitated by ChIP
of TEL-AML1-associated DNA overlapped (Figure 4).
Analysis of AML1-binding site enrichment
As most TEL-AML1-direct targets were not detected in AML1 ChIP
assays, we tested whether the binding of the fusion protein to
DNA was indeed conferred through the canonical AML1-binding
motif ‘TGYGGTY’ as expected from a previous study.12 To correct
for different lengths of identiﬁed promoter regions in the ChIP
experiments, we normalized the number of binding sites to 1 kb of
promoter region. Promoter regions of the microarray used for the
ChIP experiment carried on average 0.9 AML1-binding sites/1 kb
(±0.4,±1s.d.) and were used as background for statistical testing
using a Student’s t-test. Direct targets were signiﬁcantly enriched
over background in AML1-binding sites with 2.6 AML1-binding
sites/1 kb (±1.7; ±1 s.d.; P-value o0.001), whereas promoters of
genes whose mRNAs and proteins were regulated indirectly upon
TEL-AML1 expression were not (0.9±0.5 AML1-binding sites/1 kb;
mean±1 s.d.; P-value¼ 0.144). As expected, those 31 genes,
whose promoters and gene products were identiﬁed by all three
methods showed highest enrichment in AML1-binding sites
(2.3±0.9 AML1-binding sites/1 kb; P-valueo0.001). We therefore
concluded that indeed we could distinguish direct and indirect
TEL-AML1 targets by our approach, whereas using solely
information on mRNA expression would have obscured this result.
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Figure 2. Experimental design of the study. TEL-AML1 inducible BA/F3 cells were characterized by chromatin immunoprecipitation (ChIP-
on-chip, left panel), gene expression microarrays (middle panel) or stable isotope labelling of amino acids in cell culture (SILAC, right panel).
Empty vector controls (TA ) were compared with TEL-AML1-induced cell lines (TAþ ). In case of SILAC, both conditions were labelled with
different molecular weight amino acids as indicated and analyzed by mass spectrometry. For ChIP-on-chip and gene expression microarrays
results were obtained separately for induced and non-induced cells. The respective results were then compared with each other to identify
differential regulated and expressed genes. Please note that both, ChIP and gene expression arrays, were performed on the very same cell
culture populations in order to achieve high comparability of these two methods. For TEL-AML1, experiments were performed in biological
duplicates, whereas ChIP-on-chip for TEL and AML1 were performed in triplicates. Abbreviation: IVT, in vitro transcription.
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Functional annotation of TEL-AML1-regulated genes
To assess the global downstream functional consequence of
TEL-AML1 transcriptional regulation, we investigated the
functional annotation of TEL-AML1-regulated genes with con-
comitant change in protein output. Upregulated genes were
enriched mainly in unspeciﬁc intracellular and cytoplasm struc-
tural components. In contrast, we could identify 48 GO terms and
9 functional protein terms enriched speciﬁcally for downregulated
genes (Supplementary Table 3). Of those, 46 GO terms were also
represented by genes identiﬁed as direct targets in this study.
Translation-related GO terms were the most enriched
(GO:0006412, Po0.001) represented by 20% of downregulated
genes. GO term clustering (Supplementary Table 4) revealed
downregulation of mRNAs with simultaneous protein changes
of genes involved in a cascade of translational processes (cluster 1,
5 and 6), noncoding RNA biogenesis and metabolism (clusters
3 and 9) and methylation-related processes (cluster 8) aside from
structural clusters. In all processes, direct targets of TEL-AML1
expression were also identiﬁed by TEL-AML1 immunoprecipita-
tion, leading to a complex phenotype with a focus on translational
processes as possible early events in the selective advantage of a
pre-leukemic clone carrying the TEL-AML1 fusion protein.
Comparison with gene expression data of TEL-AML1-positive
patients
We next investigated whether the regulation of early direct
TEL-AML1 targets identiﬁed in our mouse precursor B-cell model
persist up to leukaemia-onset in paediatric patients. Therefore, we
recorded the differential expression of mRNAs from children with
precursor-B-ALL with TEL-AML1 fusion protein in comparison
to normal CD19þ cells (Figure 5a, Supplementary Table 5).
In addition, we used data from a previously published paediatric
ALL patient cohort with a total of 132 primary specimen including
20 patients with TEL-AML1.35 Twenty-three of the downregulated
and thirty of the upregulated mRNAs, which were directly targeted
by TEL-AML1 in our model, were also concomitantly regulated in
at least one of the two patient cohorts at signiﬁcance level
(Supplementary Table 6), again most of them not found in TEL or
AML1 immunoprecipitation experiments. Four mRNAs were not
uni-directional regulated in at least one of the patient cohorts and
our cell line model. Quantitative reverse transcription-PCR of
directly targeted mRNAs of ﬁve selected genes (PDLIM5, INTS2,
RSL1D1, METAP2 and GNB2L1) covering the range of down-
regulation as determined in our cell line model conﬁrmed those as
downregulated in our patient cohort (Figure 5b).
GO and functional annotation of directly downregulated mRNAs
in our cell line model and patients revealed terms related to cell
proliferation and homeostasis, splicing, noncoding RNA proces-
sing, cellular transport mechanisms and receptor signalling
pathways (Supplementary Table 7). Interestingly, the genes
encoding for Strap and Smurf2, both negative regulators of
transforming growth factor-b (TGF-b) signalling36,37 were among
the identiﬁed downregulated genes. Genes identiﬁed to be
directly upregulated could be speciﬁcally sorted into GO terms
mainly related to cellular adhesion and migration, cellular stress
response, regulation of transcription, cell cycle and, interestingly,
immune response (Supplementary Table 8). Hence, TEL-AML1
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Figure 3. TEL-AML1 chromatin immunoprecipitation in induced
BA/F3 cells. (a) Western blot (WB) analysis of TEL-AML1 chromatin
immunoprecipitation (right) show precipitation of TEL-AML1
compared with an unspecific isotype control (left). Light (arrow)
and heavy (*) band of the IP antibodies are marked. (b) Intersections
of the identified promoter regions bound by TEL-AML1 (ChIP-
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circle) and differentially expressed proteins (white circle). Directly
regulated TEL-AML1 target genes were found in the intersection of
ChIP-on-chip and gene expression analysis, whereas the intersection
of gene expression and proteomics contained the indirectly affected
genes. Abbreviations: IP, immunoprecipitation; WB, western blot.
Table 1. Directly regulated TEL-AML1 target genes with concomitant
change in protein level
Mouse ensemble Symbol mRNA Protein
gene ID Log2-FC T/Aþ
vs T/A
Ratio T/Aþ
vs. T/A
ensmusg21185 9030617O03Rik 1.85 1.41
ensmusg37405 Icam1 1.26 2.43
ensmusg24589 Nedd4l 1.16 2.12
ensmusg15733 Capza2 1.03 1.44
ensmusg28559 Osbpl9 0.95 2.10
ensmusg29440 Psmd9 0.75 1.18
ensmusg03546 Klc4 0.74 1.22
ensmusg36112 Metap2  0.61 0.80
ensmusg04535 Tax1bp1  0.66 0.61
ensmusg56201 Cfl1  0.7 1.18
ensmusg18068 Ints2  0.87 0.84
ensmusg60093 Hist1h4a  0.89 1.21
ensmusg69266 Hist1h4b  0.89 1.21
ensmusg60678 Hist1h4c  0.89 1.21
ensmusg61482 Hist1h4d  0.89 1.21
ensmusg69274 Hist1h4f  0.89 1.21
ensmusg60981 Hist1h4h  0.89 1.21
ensmusg60639 Hist1h4i  0.89 1.21
ensmusg67455 Hist1h4j  0.89 1.21
ensmusg64288 Hist1h4k  0.89 1.21
ensmusg69306 Hist1h4m  0.89 1.21
ensmusg69305 Hist1h4n  0.89 1.21
ensmusg91405 Hist2h4  0.89 1.21
ensmusg68851 Hist4h4  0.89 1.21
ensmusg59796 Eif4a1  0.97 0.76
ensmusg20706 Ftsj3  1.08 0.78
ensmusg32185 Carm1  1.11 0.79
ensmusg21692 Dimt1  1.12 0.74
ensmusg28273 Pdlim5  1.21 0.60
ensmusg05846 Rsl1d1  1.29 0.79
ensmusg27533 Fabp5  1.42 0.75
Genes were identified in our BA/F3 cell line model using chromatin
immunoprecipitation (ChIP)-on-chip and gene expression. Genes with
changes in protein output as identified by stable isotope labelling by
amino acids in cell culture (SILAC) are given. Please note that Cfl1 is
downregulated on mRNA level, but exhibits higher protein levels because
of enhanced protein stability.
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exerts an early repressive effect on translation as well as
epigenetic processes like methylation as exempliﬁed by our cell
line model and a persisting inhibitory effect on cellular processes
involving cell proliferation. A persisting positive effect could be
identiﬁed on cellular stress responses including immune
responses. This is leading to a complex early homeostatic function
of TEL-AML1 in our pre-disposition cell line model as well as its
prevalence in TEL-AML1-positive leukemic patients.
DISCUSSION
Several mRNA proﬁling studies using microarray technology have
been used to identify genes differentially regulated in TEL-AML1-
positive patients in comparison to other subgroups.19,35,38–40
However, the direct targets of the fusion transcript in early
pre-leukemic cells have only been identiﬁed for single candidates.
We therefore aimed to ﬁrst globally identify and distinguish direct
and indirect TEL-AML1 targets using a cell line model and screen a
TEL-AML1-positive patient cohort to validate those. In order to
avoid detection of effects because of secondary aberrations as
present in patient samples and the patient-derived cell lines
carrying a TEL-AML1 fusion, we used an established in vitro pro-
B-cell progenitor cell line with inducible TEL-AML1 fusion protein.22
This cell model closely resembles the cell stage previously shown
to harbour the translocation in contrast to hematopoietic stem-
and precursor cells.4 Nonetheless, we cannot rule out that other
cell stages may contribute to the pre-leukemic phenotype in
patients. Our study revealed promoter regions corresponding to
217 genes binding to TEL-AML1 and being differentially expressed
on mRNA level after TEL-AML1 induction. This is by far less than
the over 400 mRNAs downregulated after TEL-AML1 knockdown
using an small hairpin RNA approach20 or the over 2500
downregulated genes in TEL-AML1-positive patients samples
compared with TEL-AML1-negative patient samples.26 This
difference might be attributed to the lack of secondary
aberrations because of the short induction time and the
possibility to distinguish between direct and indirect targets in
our study. Other species-speciﬁc and cell line-speciﬁc B-cell
maturation effects might as well account for the difference
between the mouse and the human data sets. For examples,
the BA/F3 cells, described to mature to Ig-producing cells in vivo,41
do not express Pax5,42 a factor shown to be indispensable
for B-cell lineage maintenance and maturation.43 However,
TEL-AML1-bound regions of the human precursor B-ALL cell line
NALM-6 stably expressing the fusion construct showed
overlapping regions with the regions identiﬁed in BA/F3. In
addition, our approach let us to identify 118 mRNAs and proteins
indirectly regulated by TEL-AML1 expression, most of them
unidirectional. The mRNA of Rab8b was the only mRNA
upregulated with concomitant downregulation of the protein
level. The 30-untranslated region of the corresponding transcript
indeed harbours a predicted miRNA binding site for miR-19a/b
that were induced upon TEL-AML1 expression. Rab8b, a member
of the Ras oncogene family, has been implicated in vesicular
transport44 and has been recently discovered as sensitizer to
bortezomib in multiple myeloma.45
The binding and thus function of the TEL-AML1 fusion protein
has been proposed to be mediated through the Runt DNA-
binding domain of the AML1 fusion part.46 Indeed, we identiﬁed a
statistical signiﬁcant enrichment over background of the canonical
AML1-binding motif in direct TEL-AML1 target promoters in this
study in contrast to the use of merely mRNA expression data in a
knockdown study of TEL-AML1.20 As 88% of identiﬁed direct
target promoters were speciﬁc for TEL-AML1 as compared with
TEL and AML1 ChIP in this study and very recent AML1 ChIP-seq
results,34 other determinants of binding seem to be involved.
These might be differences in co-factors or higher afﬁnity binding
to DNA of the fusion protein itself as has been shown for the
Figure 4. Comparison of immunoprecipitated chromosomal regions. Regions precipitated with the TEL-AML1 antibody from NALM-6 cells
stably expressing the fusion transcript were mapped to human chromosomal regions (black bars) and compared with regions
immunoprecipitated from the induced mouse Ba/F3 cell line (grey bars). The densities of regions are blotted horizontally.
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AML1-ETO and inv-16 triggered AML1 fusion proteins47,48 and
proposed for the TEL-AML1 fusion protein as well.46
Mainly repressive GO terms are enriched in regulated genes of
TEL-AML1 as identiﬁed here. This is in line with repressive function
previously exempliﬁed for single TEL-AML1 targets (reviewed in
Zelent et al.46) as well as globally in a small hairpin RNA-mediated
cell culture knockdown study.20 The downregulated translational
processes might resemble the differentiation arrest described
as early event of TEL-AML1 expression.7 Furthermore, genes
involved in acetylation and methylation processes were also
downregulated as direct consequence of TEL-AML1 induction with
binding of TEL-AML1 fusion protein to the respective promoter
regions, stressing the importance of epigenetic mechanisms for
modulation of transcription factor activity. These direct targets
included granzyme B, previously shown to be repressed by the
fusion protein through recruitment of histone deacetylases.26
To investigate if identiﬁed early direct targets of TEL-AML1 in a
progenitor B-cell model persist in the leukemic blasts at diagnosis,
we evaluated gene expression in children with TEL-AML1-positive
ALL compared with CD19þ cells of healthy donors or compared
with TEL-AML1-negative ALL patients.35 A total of 53 genes were
still signiﬁcantly differentially regulated in either study after years
of TEL-AML1 expression and multiple other factors absent in our
cell culture model.49 The persistence of direct TEL-AML1 effects in
two independent patient cohorts is in line with an in vivo
transplantation mouse study, which showed an indispensable
role of the fusion protein for cell survival and replenishment.21
Greaves et al. described a persistent growth of TEL-AML1-induced
BA/F3 cells after TGF-b treatment, whereas without TGF-b TEL-
AML1-induced cells had a growth disadvantage over control cells.22
We identiﬁed a binding of TEL-AML1 to promoter regions and a
concomitant downregulation of the mRNA of inhibitors of the
‘classical’ SMAD-dependent TGF-b pathway, STRAP and SMURF2,
which were also found in TEL-AML1-positive patients at signiﬁcant
levels. It has been demonstrated that the TEL-AML1 fusion protein
binds to Smad3 downstream of its activation, thus impairing signal
transduction of the ‘classical’ TGF-b pathway. However, the possible
hyperactivation of TGF-b receptors through downregulation of
negative effectors might also result in activation of Smad-
independent TGF-b receptor-mediated pathways like the JNK,
p38MAPK or Erk/MAPK pathways (reviewed in Derynck and Zhan50).
We ﬁnd the mRNA of DUSP7, an inactivator of ERKs, directly
upregulated after TEL-AML1 induction; however, it was not
identiﬁed as signiﬁcantly regulated in patients. Aside from the
TGF-b pathway, Smurf2 deﬁciency has been shown to attenuate
p16 expression thus impairing senescence response and increasing
the susceptibility of mice for spontaneous tumorigenesis of mainly
B-cell lymphoma.51 Furthermore, ablation of Smurf2 leads to
dysregulation of the epigenetic landscape through histone
modiﬁcations and thus loss of chromosomal stability in a mouse
model leading to a wide range of malignancies including
lymphomas.52
In summary, we globally identiﬁed early direct and indirect
targets of the TEL-AML1 fusion protein by integration of
chromatin immunoprecipitation, mRNA expression and differential
stable isotope labelling of proteins from the same cell system for
the ﬁrst time. Unexpectedly, TEL-AML1 binds to speciﬁc promoter
regions mostly distinct from AML1-bound promoter regions in
murine cell line models, although binding seems to be, at least in
part, mediated by the Runt DNA-binding domain as the consensus
signal is enriched in direct targets over background and also over
indirect TEL-AML1 targets deﬁned here. We could also demon-
strate an immediate suppressive effect on mRNA transcription
upon TEL-AML1 promoter binding resulting in enrichment of
respective biological processes and pathways only for down-
regulated genes. Our work represents a resource for the future
in vitro and more importantly in vivo study of the underlying cause
of premalignant transformation of early lymphoid precursors in
the development of TEL-AML1-positive ALL and is useful
for interpretation of patient-derived data as exempliﬁed on two
patient cohorts in this work.
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Figure 5. Differential gene expression in TEL-AML1-positive patients.
(a) The 150 most variant differentially expressed genes between four
TEL-AML1-positive pre-B-ALL patients and two CD19-positive
healthy donor controls (Ctrls) are shown. Unsupervised hierarchical
clustering of samples using the Ward method revealed a separation
of patients and normal Ctrls. (b) mRNAs of five direct TEL-AML1
targets covering the range of downregulation as determined in our
cell line model were validated by quantitative reverse transcription-
PCR in our patient cohort and compared with normal Ctrls.
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